cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.mgj9xk
title: Occurrence Download

description: A dataset containing 13319 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON ((14.16751398 47.67898893, 14.55440852 47.67898893, 14.55440852 47.85659594, 14.16751398 47.85659594, 14.16751398 47.67898893))",
 "TaxonKey is one of (Bombina variegata, Actitis hypoleucos, Aegolius funereus, Aquila chrysaetos, Bonasa bonasia, Bubo bubo, Caprimulgus europaeus, Ciconia nigra, Circaetus gallicus, Columba oenas, Dendrocopos leucotos, Dryocopus martius, Falco peregrinus, Ficedula albicollis, Ficedula hypoleuca, Ficedula parva, Glaucidium passerinum, Lagopus muta, Lanius collurio, Muscicapa striata, Pernis apivorus, Picoides tridactylus, Picus canus, Scolopax rusticola, Tetrao tetrix, Tetrao urogallus, Cottus gobio, Austropotamobius torrentium, Cucujus cinnaberinus, Euphydryas aurinia, Euphydryas maturna, Euplagia quadripunctaria, Rosalia alpina, Stephanopachys substriatus, Barbastella barbastellus, Lutra lutra, Lynx lynx, Myotis bechsteinii, Myotis emarginatus, Myotis myotis, Rhinolophus hipposideros, Ursus arctos, Buxbaumia viridis, Cypripedium calceolus, Dicranum viride, Scapania carinthiaca)"
 ]
}

 The dataset includes 13319 records from 16 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006663-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fztxk9
title: Occurrence Download

description: A dataset containing 158 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Llagunoa nitida",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 158 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006667-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25919/3b9t-6f33
title: Parkes observations for project P1386 semester 2025OCTS_17

description: J0045-7319 is a B star/pulsar binary in the Small Magellanic Cloud (SMC) with an orbital period of 51 days. The system is highly eccentric, with a closest approach of only 6 B-star radii, and it offers an unusual probe into massive stars in the SMC. Although similar systems exhibit strong dispersion measure (DM) variation during periastron arising from the stellar wind, observations in 1996 on the Parkes 70 cm receiver found no evidence of a wind from the B star. We propose a new set of observations on the Ultra-Wide Low-frequency receiver (UWL) designed to measure the wind. A null result will decrease the known upper limit on the B-star wind's contribution to DM by a factor of 9.
DOI: 10.7910/dvn/iv10nr
title: Replication Data for: On the Link Between Capital Stock and Carbon Dioxide Emissions in Europe: Assessing Environmental Efficiency.

description: The files in this replication package relate to the article “On the Link Between Capital Stock and Carbon Dioxide Emissions in Europe: Assessing Environmental Efficiency.” The package contains the dataset, accompanying metadata, and the scripts required to reproduce the empirical outputs reported in the paper.
File overview
• Database.xlsx
This Excel workbook contains two worksheets:
• Database: the main dataset used in the empirical analysis.
• METADATA: documentation for each variable, including the variable acronym/name, a brief description, units of measurement, the original data source, and a hyperlink to the corresponding source.
• Script Tables.do
Stata do-file that imports and processes the data and produces the results reported in the paper’s tables.
• Script Figures.R
R script that generates the figures reported in the paper.
How to run
1. Open Script Tables.do in Stata and run the full script to reproduce the table outputs.
2. Run Script Figures.R in R (or RStudio) to reproduce the figures.
All variables and their definitions, units, and sources are described in the METADATA worksheet of Database.xlsx.
DOI: 10.15468/dl.uh34gn
title: Occurrence Download

description: A dataset containing 13319 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON ((14.16751398 47.67898893, 14.55440852 47.67898893, 14.55440852 47.85659594, 14.16751398 47.85659594, 14.16751398 47.67898893))",
 "TaxonKey is one of (Bombina variegata, Actitis hypoleucos, Aegolius funereus, Aquila chrysaetos, Bonasa bonasia, Bubo bubo, Caprimulgus europaeus, Ciconia nigra, Circaetus gallicus, Columba oenas, Dendrocopos leucotos, Dryocopus martius, Falco peregrinus, Ficedula albicollis, Ficedula hypoleuca, Ficedula parva, Glaucidium passerinum, Lagopus muta, Lanius collurio, Muscicapa striata, Pernis apivorus, Picoides tridactylus, Picus canus, Scolopax rusticola, Tetrao tetrix, Tetrao urogallus, Cottus gobio, Austropotamobius torrentium, Cucujus cinnaberinus, Euphydryas aurinia, Euphydryas maturna, Euplagia quadripunctaria, Rosalia alpina, Stephanopachys substriatus, Barbastella barbastellus, Lutra lutra, Lynx lynx, Myotis bechsteinii, Myotis emarginatus, Myotis myotis, Rhinolophus hipposideros, Ursus arctos, Buxbaumia viridis, Cypripedium calceolus, Dicranum viride, Scapania carinthiaca)"
 ]
}

 The dataset includes 13319 records from 16 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006669-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ej2y8j
title: Occurrence Download

description: A dataset containing 67 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "TaxonKey is Pinus pumila"
 ]
}

 The dataset includes 67 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006671-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.27969424
title: Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database

description: Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second quarter (Q2) of 2019 to the fourth quarter (Q4) of 2023 from the FDA adverse event reporting system (FAERS) database. The AE data related to tafamidis from 2019 Q2 to 2023 Q4 were collected and standardized. Various signal quantification techniques, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker, were employed for analysis. Among the 8742 AE reports with tafamidis as the primary suspected drug, 180 preferred terms of AEs spanning 27 different system organ classes were identified. Unique adverse events to tafamidis included renal and urinary disorders and ear and labyrinth disorders, with not mentioned in the official drug label. Additionally, uncommon but significantly strong AE signals, such as blood culture positive and acquired hemophilia, were observed. Common AEs with relatively high occurrence rates included death, off-label use, fall, hypoacusis, and dysphagia. These findings offer valuable insights for optimizing the use of tafamidis and reducing potential side effects, thereby facilitating its safe use in clinical settings.
DOI: 10.6084/m9.figshare.27969424.v2
title: Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database

description: Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second quarter (Q2) of 2019 to the fourth quarter (Q4) of 2023 from the FDA adverse event reporting system (FAERS) database. The AE data related to tafamidis from 2019 Q2 to 2023 Q4 were collected and standardized. Various signal quantification techniques, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker, were employed for analysis. Among the 8742 AE reports with tafamidis as the primary suspected drug, 180 preferred terms of AEs spanning 27 different system organ classes were identified. Unique adverse events to tafamidis included renal and urinary disorders and ear and labyrinth disorders, with not mentioned in the official drug label. Additionally, uncommon but significantly strong AE signals, such as blood culture positive and acquired hemophilia, were observed. Common AEs with relatively high occurrence rates included death, off-label use, fall, hypoacusis, and dysphagia. These findings offer valuable insights for optimizing the use of tafamidis and reducing potential side effects, thereby facilitating its safe use in clinical settings.
DOI: 10.6084/m9.figshare.31229159
title: A multidisciplinary lifestyle programme for patients with rheumatoid arthritis and metabolic syndrome-associated osteoarthritis: economic evaluation alongside the ‘Plants for Joints’ randomized controlled trials

description: To evaluate the cost-effectiveness of the ‘Plants for Joints’ intervention for rheumatoid arthritis (RA) and metabolic syndrome-associated osteoarthritis (MSOA) patients over 16 weeks. Data from two randomized controlled trials were analysed. The first included 77 RA patients (intervention = 40; control = 37) and the second 64 MSOA patients (intervention = 32; control = 32). The intervention comprised a 16 week lifestyle programme including a whole-food plant-based diet, exercise, and stress management; control participants received usual care. Data from both trials were analysed together and separately. Costs were measured from societal and healthcare perspectives. Effects were expressed in quality-adjusted life-years (QALYs). The intervention cost €886/patient. Intervention group participants gained more QALYs than the control group (0.009; 95% confidence interval −0.004 to 0.023), equivalent to 3.3 additional days in ‘perfect health’ (0.009 × 365). Healthcare costs were higher in the intervention group, while societal costs were lower. None of these differences was statistically significant. From a societal perspective, the intervention had a moderate to high probability of being cost-effective compared with usual care, while the probability was low from a healthcare perspective. Stratified analyses indicated that the probability of cost-effectiveness was higher in RA than in MSOA patients. This difference became less pronounced after excluding outliers. The Plants for Joints intervention demonstrated a relatively high probability of cost-effectiveness from a societal perspective, although this was lower from a healthcare perspective. If these benefits are sustained in the long term, this intervention may reduce the disease and economic burden of arthritic conditions.
DOI: 10.6084/m9.figshare.31229159.v1
title: A multidisciplinary lifestyle programme for patients with rheumatoid arthritis and metabolic syndrome-associated osteoarthritis: economic evaluation alongside the ‘Plants for Joints’ randomized controlled trials

description: To evaluate the cost-effectiveness of the ‘Plants for Joints’ intervention for rheumatoid arthritis (RA) and metabolic syndrome-associated osteoarthritis (MSOA) patients over 16 weeks. Data from two randomized controlled trials were analysed. The first included 77 RA patients (intervention = 40; control = 37) and the second 64 MSOA patients (intervention = 32; control = 32). The intervention comprised a 16 week lifestyle programme including a whole-food plant-based diet, exercise, and stress management; control participants received usual care. Data from both trials were analysed together and separately. Costs were measured from societal and healthcare perspectives. Effects were expressed in quality-adjusted life-years (QALYs). The intervention cost €886/patient. Intervention group participants gained more QALYs than the control group (0.009; 95% confidence interval −0.004 to 0.023), equivalent to 3.3 additional days in ‘perfect health’ (0.009 × 365). Healthcare costs were higher in the intervention group, while societal costs were lower. None of these differences was statistically significant. From a societal perspective, the intervention had a moderate to high probability of being cost-effective compared with usual care, while the probability was low from a healthcare perspective. Stratified analyses indicated that the probability of cost-effectiveness was higher in RA than in MSOA patients. This difference became less pronounced after excluding outliers. The Plants for Joints intervention demonstrated a relatively high probability of cost-effectiveness from a societal perspective, although this was lower from a healthcare perspective. If these benefits are sustained in the long term, this intervention may reduce the disease and economic burden of arthritic conditions.
DOI: 10.6084/m9.figshare.27275244
title: Mining and analysis of adverse event signals of vandetanib based on the FAERS database

description: By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug. This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023. Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect. The analyses yielded 187 AEs signals across 20 SOCs categories, with 47 signals not previously reported in the vandetanib labeling. Additionally, the study analyzes factors influencing AEs. The results are as follows: There are significant differences in Investigations based on gender and nationality (<i>p</i> &lt; 0.05); skin and subcutaneous tissue disorders and gastrointestinal disorders exhibit differences based on gender, age, and nationality (<i>p</i> &lt; 0.05). Common AEs signals identified align with those documented in the drug labeling. However, AEs such as tumor lysis syndrome, skin discoloration, and pigmentary disorders, which are not listed in the labeling, warrant special attention. It is essential that abnormalities in patients’ skin and laboratory indicators are closely monitored and addressed promptly to safeguard medication safety.
DOI: 10.6084/m9.figshare.27275244.v1
title: Mining and analysis of adverse event signals of vandetanib based on the FAERS database

description: By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug. This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023. Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect. The analyses yielded 187 AEs signals across 20 SOCs categories, with 47 signals not previously reported in the vandetanib labeling. Additionally, the study analyzes factors influencing AEs. The results are as follows: There are significant differences in Investigations based on gender and nationality (<i>p</i> &lt; 0.05); skin and subcutaneous tissue disorders and gastrointestinal disorders exhibit differences based on gender, age, and nationality (<i>p</i> &lt; 0.05). Common AEs signals identified align with those documented in the drug labeling. However, AEs such as tumor lysis syndrome, skin discoloration, and pigmentary disorders, which are not listed in the labeling, warrant special attention. It is essential that abnormalities in patients’ skin and laboratory indicators are closely monitored and addressed promptly to safeguard medication safety.
DOI: 10.6084/m9.figshare.27969424.v1
title: Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database

description: Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second quarter (Q2) of 2019 to the fourth quarter (Q4) of 2023 from the FDA adverse event reporting system (FAERS) database. The AE data related to tafamidis from 2019 Q2 to 2023 Q4 were collected and standardized. Various signal quantification techniques, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker, were employed for analysis. Among the 8742 AE reports with tafamidis as the primary suspected drug, 180 preferred terms of AEs spanning 27 different system organ classes were identified. Unique adverse events to tafamidis included renal and urinary disorders and ear and labyrinth disorders, with not mentioned in the official drug label. Additionally, uncommon but significantly strong AE signals, such as blood culture positive and acquired hemophilia, were observed. Common AEs with relatively high occurrence rates included death, off-label use, fall, hypoacusis, and dysphagia. These findings offer valuable insights for optimizing the use of tafamidis and reducing potential side effects, thereby facilitating its safe use in clinical settings.
DOI: 10.6084/m9.figshare.28071715
title: Post-marketing safety of panitumumab: a real-world pharmacovigilance study

description: Panitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to extract real-world panitumumab ADR signals and provide relevant information for drug safety. ROR, PRR, BCPNN, and MGPS were used to identify real-world ADR signals associated with panitumumab. Analysis of 9,033 patients identified 263 ADR signals across 20 MedDRA System Organ Classifications. New signals including peripheral sensory neuropathy, gene mutation, decreased neutrophil count, polyneuropathy, ileus, neutropenia, and febrile neutropenia. Age and sex subgroup analyses revealed specific risks, such as polyneuropathy and gene mutation in those under 65 years of age, decreased neutrophil count and peripheral sensory neuropathy in those over 65 years of age, and febrile neutropenia in men. Ileus was highlighted as a novel ADR in gastrointestinal disorders, with no significant age or sex differences. This study identified new signals of ADR associated with panitumumab, providing valuable information for the clinical use of panitumumab.
DOI: 10.6084/m9.figshare.28071715.v1
title: Post-marketing safety of panitumumab: a real-world pharmacovigilance study

description: Panitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to extract real-world panitumumab ADR signals and provide relevant information for drug safety. ROR, PRR, BCPNN, and MGPS were used to identify real-world ADR signals associated with panitumumab. Analysis of 9,033 patients identified 263 ADR signals across 20 MedDRA System Organ Classifications. New signals including peripheral sensory neuropathy, gene mutation, decreased neutrophil count, polyneuropathy, ileus, neutropenia, and febrile neutropenia. Age and sex subgroup analyses revealed specific risks, such as polyneuropathy and gene mutation in those under 65 years of age, decreased neutrophil count and peripheral sensory neuropathy in those over 65 years of age, and febrile neutropenia in men. Ileus was highlighted as a novel ADR in gastrointestinal disorders, with no significant age or sex differences. This study identified new signals of ADR associated with panitumumab, providing valuable information for the clinical use of panitumumab.
DOI: 10.6084/m9.figshare.30876683.v1
title: Pharmacological strategies for treating social anxiety disorder in adults: a Systematic review of studies published since 2015

description: Social anxiety disorder (SAD) is a common and disabling mental disorder that follows a chronic course unless it is treated with effective treatments. This systematic review examines randomized controlled trials (RCTs) of pharmacological treatments for adults with SAD published since 2015. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Search was conducted on PubMed, Scopus, Web of Science, and PsycINFO. Risk of bias of the included studies was assessed using the Cochrane risk of bias tool for randomized trials. Eighteen RCTs were included. Selective serotonin reuptake inhibitors (SSRIs) were the most investigated pharmacological intervention, either as monotherapy or in combination with cognitive behavioral therapy (CBT). More recent drugs show promising results include cannabidiol and d-cycloserine. When CBT is unavailable, SSRIs are the first-line pharmacological treatment for SAD based on current evidence. However, response rates vary substantially. We recommend a personalized approach that includes patient preference and treatment accessibility.
DOI: 10.5281/zenodo.18455295
title: Principles, Clinical  Applications, and Case Management The 2 by 4 Appliance in Pediatric Dentistry A clinical guide

description: nlock the power of early intervention with Mastering the 2x4 Appliance—your essential guide to one of orthodontics' most effective tools for treating mixed dentition cases. Designed for forward-thinking orthodontists, pediatric dentists, and general practitioners, this practical and visually rich book shows you how to harness the 2x4 fixed appliance to quickly correct anterior crossbites, align incisors, and simplify complex cases—before full braces are even needed. Inside, you'll discover: ➢ Clear, step-by-step protocols for appliance design, bonding, and wire sequencing ➢ High-impact clinical cases with stunning beforeand-after photos ➢ Tips and tricks to minimize chair time and maximize patient cooperation ➢ How to use the 2x4 for space management, eruption guidance, and arch development ➢ Solutions to common pitfalls with real-world troubleshooting advice ➢ Whether you're just starting to integrate fixed appliances into your early treatment plans or looking to refine your existing approach, this book delivers clinical confidence and immediate results. Early treatment. Better outcomes. Happier patients. Let the 2x4 appliance transform the way you practice— one smile at a time.
DOI: 10.5281/zenodo.18455294
title: Principles, Clinical  Applications, and Case Management The 2 by 4 Appliance in Pediatric Dentistry A clinical guide

description: nlock the power of early intervention with Mastering the 2x4 Appliance—your essential guide to one of orthodontics' most effective tools for treating mixed dentition cases. Designed for forward-thinking orthodontists, pediatric dentists, and general practitioners, this practical and visually rich book shows you how to harness the 2x4 fixed appliance to quickly correct anterior crossbites, align incisors, and simplify complex cases—before full braces are even needed. Inside, you'll discover: ➢ Clear, step-by-step protocols for appliance design, bonding, and wire sequencing ➢ High-impact clinical cases with stunning beforeand-after photos ➢ Tips and tricks to minimize chair time and maximize patient cooperation ➢ How to use the 2x4 for space management, eruption guidance, and arch development ➢ Solutions to common pitfalls with real-world troubleshooting advice ➢ Whether you're just starting to integrate fixed appliances into your early treatment plans or looking to refine your existing approach, this book delivers clinical confidence and immediate results. Early treatment. Better outcomes. Happier patients. Let the 2x4 appliance transform the way you practice— one smile at a time.